Roche Inks $80M Upfront Deal for Hansoh’s Cancer ADC HS-20110

Roche; Hansoh Pharmaceutical; ADC; HS-20110; CDH17; colorectal cancer; solid tumors; licensing deal; upfront payment; milestone payments; royalties

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal

GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac

XtalPi and DoveTree Announce Landmark $6 Billion AI-Powered Drug Discovery Collaboration

XtalPi; DoveTree Medicines; AI drug discovery; robotics; pharmaceutical R&D; Gregory Verdine; oncology; immunology; neurology; metabolic diseases; collaboration; upfront payment; milestone payments; royalties

Merck KGaA Bolsters Protein Degradation Pipeline with $756M C4 Therapeutics Partnership

Merck KGaA, C4 Therapeutics, Targeted Protein Degradation, Collaboration, $756M Deal, Oncogenic Proteins, TORPEDO® Platform, Mid-Single to Low-Double Digit Tiered Royalties, Upfront Payment: $16 Million, Potential Milestone Payments: Up to $740 Million